BioAge Labs, Inc. has announced promising Phase 1 clinical trial results for BGE-102, a novel small molecule NLRP3 inhibitor designed to target inflammation associated with metabolic diseases. The trial evaluated a 60 mg once-daily dosing regimen over 21 days in participants with obesity and elevated inflammation, revealing significant reductions in high-sensitivity C-reactive protein (hsCRP) and other inflammatory biomarkers. Notably, the 60 mg dose exhibited reductions in hsCRP comparable to those seen with a previously tested 120 mg dose, alongside a favorable safety profile.

These findings underscore the potential of BGE-102 as a best-in-class NLRP3 inhibitor, with profound implications for cardiovascular health. The reduction in hsCRP, a key biomarker for cardiovascular risk, aligns with previous studies indicating that lowering hsCRP levels below 2 mg/L correlates with a 25% decrease in major adverse cardiovascular events. The consistent biomarker improvements observed at both dosing levels suggest that BGE-102 could effectively mitigate inflammation-driven cardiovascular risks, akin to the transformative impact of statins on LDL cholesterol management.

The implications for future research and drug development are significant. BioAge plans to initiate a Phase 2 dose-ranging trial in early 2026, focusing on cardiovascular risk, with results expected later that year. Additionally, a proof-of-concept trial in diabetic macular edema is set for mid-2026, further expanding BGE-102’s therapeutic potential. This strategic advancement not only positions BGE-102 as a promising candidate for addressing NLRP3-related inflammation but also signals a shift in how oral therapies could be utilized in the prevention and management of chronic diseases associated with aging.

Source: lifespan.io